Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project.


Journal

Mutagenesis
ISSN: 1464-3804
Titre abrégé: Mutagenesis
Pays: England
ID NLM: 8707812

Informations de publication

Date de publication:
06 03 2019
Historique:
received: 08 08 2018
accepted: 20 09 2018
pubmed: 26 10 2018
medline: 27 4 2019
entrez: 26 10 2018
Statut: ppublish

Résumé

The International Conference on Harmonization (ICH) M7 guideline allows the use of in silico approaches for predicting Ames mutagenicity for the initial assessment of impurities in pharmaceuticals. This is the first international guideline that addresses the use of quantitative structure-activity relationship (QSAR) models in lieu of actual toxicological studies for human health assessment. Therefore, QSAR models for Ames mutagenicity now require higher predictive power for identifying mutagenic chemicals. To increase the predictive power of QSAR models, larger experimental datasets from reliable sources are required. The Division of Genetics and Mutagenesis, National Institute of Health Sciences (DGM/NIHS) of Japan recently established a unique proprietary Ames mutagenicity database containing 12140 new chemicals that have not been previously used for developing QSAR models. The DGM/NIHS provided this Ames database to QSAR vendors to validate and improve their QSAR tools. The Ames/QSAR International Challenge Project was initiated in 2014 with 12 QSAR vendors testing 17 QSAR tools against these compounds in three phases. We now present the final results. All tools were considerably improved by participation in this project. Most tools achieved >50% sensitivity (positive prediction among all Ames positives) and predictive power (accuracy) was as high as 80%, almost equivalent to the inter-laboratory reproducibility of Ames tests. To further increase the predictive power of QSAR tools, accumulation of additional Ames test data is required as well as re-evaluation of some previous Ames test results. Indeed, some Ames-positive or Ames-negative chemicals may have previously been incorrectly classified because of methodological weakness, resulting in false-positive or false-negative predictions by QSAR tools. These incorrect data hamper prediction and are a source of noise in the development of QSAR models. It is thus essential to establish a large benchmark database consisting only of well-validated Ames test results to build more accurate QSAR models.

Identifiants

pubmed: 30357358
pii: 5142926
doi: 10.1093/mutage/gey031
pmc: PMC6402315
doi:

Substances chimiques

Mutagens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-16

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society.

Références

Regul Toxicol Pharmacol. 2000 Oct;32(2):219-25
pubmed: 11067778
Mutat Res. 2000 Nov 20;455(1-2):29-60
pubmed: 11113466
Biochim Biophys Acta. 1975 Oct 20;405(2):442-51
pubmed: 1180967
Mutagenesis. 2002 Jul;17(4):321-9
pubmed: 12110629
Mutat Res. 2005 Jul 4;584(1-2):1-256
pubmed: 15979392
Mutat Res. 2005 Dec 30;588(2):129-35
pubmed: 16257575
Mutat Res. 2008 Sep-Oct;659(3):248-61
pubmed: 18621573
Environ Mol Mutagen. 2009 Jul;50(6):435-50
pubmed: 19334052
Mutagenesis. 2009 Jul;24(4):359-66
pubmed: 19447896
J Chem Inf Model. 2009 Sep;49(9):2077-81
pubmed: 19702240
Mutat Res. 1991 Jun;248(2):221-31
pubmed: 2046681
Chem Rev. 2011 Apr 13;111(4):2507-36
pubmed: 21265518
Chem Res Toxicol. 2011 Jun 20;24(6):843-54
pubmed: 21534561
Regul Toxicol Pharmacol. 2012 Apr;62(3):449-55
pubmed: 22321701
Regul Toxicol Pharmacol. 2013 Oct;67(1):39-52
pubmed: 23669331
Regul Toxicol Pharmacol. 2013 Aug;66(3):326-35
pubmed: 23688841
Mutat Res. 1990 Jan;228(1):1-50
pubmed: 2405259
Regul Toxicol Pharmacol. 2015 Jul;72(2):335-49
pubmed: 25980641
Regul Toxicol Pharmacol. 2015 Oct;73(1):367-77
pubmed: 26248005
Regul Toxicol Pharmacol. 2016 Jun;77:1-12
pubmed: 26879463
Toxicol Mech Methods. 2017 Jan;27(1):24-35
pubmed: 27813437
Regul Toxicol Pharmacol. 2018 Apr;94:172-182
pubmed: 29408293
Mutat Res. 1988 Jan;204(1):17-115
pubmed: 3277047
Ann N Y Acad Sci. 1988;534:133-8
pubmed: 3291707
Mutat Res. 1986 Sep;168(2):69-240
pubmed: 3528831
Environ Mutagen. 1985;7 Suppl 5:1-248
pubmed: 3905369
Mutat Res. 1984 Apr;126(2):139-44
pubmed: 6717454
Mutat Res. 1984 May;126(3):227-38
pubmed: 6717460
Mutat Res. 1981 Jun;85(3):119-32
pubmed: 7022184
Mutat Res. 1981 Dec;85(6):391-410
pubmed: 7040947
Mutat Res. 1996 Jul 10;369(1-2):23-31
pubmed: 8700179
Environ Mol Mutagen. 1997;29(3):312-22
pubmed: 9142175
Regul Toxicol Pharmacol. 1998 Feb;27(1 Pt 2):32-7
pubmed: 9618321

Auteurs

Masamitsu Honma (M)

Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tonomachi, Kawasaki-ku, Kanagawa, Japan.

Airi Kitazawa (A)

Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tonomachi, Kawasaki-ku, Kanagawa, Japan.

Alex Cayley (A)

Lhasa Limited, Granary Wharf House, Canal Wharf, Leeds, UK.

Richard V Williams (RV)

Lhasa Limited, Granary Wharf House, Canal Wharf, Leeds, UK.

Chris Barber (C)

Lhasa Limited, Granary Wharf House, Canal Wharf, Leeds, UK.

Thierry Hanser (T)

Lhasa Limited, Granary Wharf House, Canal Wharf, Leeds, UK.

Roustem Saiakhov (R)

MultiCASE Inc., Chagrin Blvd Ste, Beachwood, OH, USA.

Suman Chakravarti (S)

MultiCASE Inc., Chagrin Blvd Ste, Beachwood, OH, USA.

Glenn J Myatt (GJ)

Leadscope, Inc., Columbus, OH, USA.

Kevin P Cross (KP)

Leadscope, Inc., Columbus, OH, USA.

Emilio Benfenati (E)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via G. La Masa19 Milano, Italy.

Giuseppa Raitano (G)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via G. La Masa19 Milano, Italy.

Ovanes Mekenyan (O)

Laboratory of Mathematical Chemistry, As. Zlatarov University, Bourgas, Bulgaria.

Petko Petkov (P)

Laboratory of Mathematical Chemistry, As. Zlatarov University, Bourgas, Bulgaria.

Cecilia Bossa (C)

Istituto Superiore di Sanita', Viale Regina Elena, Rome, Italy.

Romualdo Benigni (R)

Istituto Superiore di Sanita', Viale Regina Elena, Rome, Italy.
Alpha-Pretox, Via G. Pascoli, Rome, Italy.

Chiara Laura Battistelli (CL)

Istituto Superiore di Sanita', Viale Regina Elena, Rome, Italy.

Alessandro Giuliani (A)

Istituto Superiore di Sanita', Viale Regina Elena, Rome, Italy.

Olga Tcheremenskaia (O)

Istituto Superiore di Sanita', Viale Regina Elena, Rome, Italy.

Christine DeMeo (C)

Prous Institute, Rambla de Catalunya, Barcelona, Spain.

Ulf Norinder (U)

Swetox, Karolinska Institutet, Unit of Toxicology Sciences, Södertälje, Sweden.
Department of Computer and Systems Sciences, Stockholm University, SE Kista, Sweden.

Hiromi Koga (H)

Fujitsu Kyushu Systems Limited, Higashihie, Hakata-ku, Fukuoka, Japan.

Ciloy Jose (C)

Fujitsu Kyushu Systems Limited, Higashihie, Hakata-ku, Fukuoka, Japan.

Nina Jeliazkova (N)

IdeaConsult Ltd., A. Kanchev str., Sofia, Bulgaria.

Nikolay Kochev (N)

IdeaConsult Ltd., A. Kanchev str., Sofia, Bulgaria.
Department of Analytical Chemistry and Computer Chemistry, University of Plovdiv, Plovdiv, Bulgaria.

Vesselina Paskaleva (V)

Department of Analytical Chemistry and Computer Chemistry, University of Plovdiv, Plovdiv, Bulgaria.

Chihae Yang (C)

Molecular Networks GmbH and Altamira LLC, Neumeyerstrasse Nürnberg, Germany and Candlewood Drive, Columbus, OH, USA.

Pankaj R Daga (PR)

Simulations Plus, Inc., CA, USA.

Robert D Clark (RD)

Simulations Plus, Inc., CA, USA.

James Rathman (J)

Molecular Networks GmbH and Altamira LLC, Neumeyerstrasse Nürnberg, Germany and Candlewood Drive, Columbus, OH, USA.
Chemical and Biomolecular Engineering, The Ohio State University, W. Woodruff Ave. Columbus, OH, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH